Annual Review of Propoxyphene Products

Oklahoma Health Care Authority September 2008

Current Prior Authorization Requirements

Approval Criteria for Darvocet A500 and Balacet 325


- Documented need to restrict acetaminophen use
- Concurrent use of acetaminophen-containing products
- Documented renal insufficiency or hepatic impairment
- A quantity limit of 180/30 on each of the products also applies.

Trends in Utilization of Propoxyphene products

Fiscal Year	Total Members	Total Claims	Total Cost	Cost per Claim	Per-Diem Cost	Total Units	Total Days
2007	17,820	33,087	\$239,618.26	\$7.24	\$0.73	1,373,780	329,214
2008	16,975	31,547	\$214,117.32	\$6.79	\$0.63	1,352,466	338,521
Percent Change	-4.7%	-4.7%	-10.6%	-6.2%	-13.7%	-1.6%	2.8%
	-845	-1,540	(\$25,500.94)	(\$0.45)	(\$0.10)	-21,314	9,307

Medication	Claims	Members	Units	Days	Cost	Units/ Day	Claims/ Member	Per- diem
Propoxyphene-N w/ APAP tab 100-650 mg	31,209	16,801	1,342,390	336,030	\$208,550.36	3.99	1.86	\$0.62
Propoxyphene-N w/ APAP tab 50- 325 mg	338	265	10,076	2,491	\$5,566.96	4.04	1.28	\$2.23
Darvocet A500	0	0	0	0	0	0	0	0
Balacet 325	0	0	0	0	0	0	0	0
Totals	31,547	16,975	1,352,466	338,521	\$214,117.32	4.00	1.86	\$0.63

Demographics of Members Utilizing Propoxyphene Products in FY 2008



Age Groups

9,774 10,000 9,000 8,000 7,000 6,000 4,568 5,000

Recommendations

The College of Pharmacy has no recommendations for this category at this time.

Prescribers of Propoxyphene Products in FY 08

